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1. Summary  
 Persistent high-risk HPV infection is the major aetiological factor for the 
development of cervical cancer, since over 99% of the cervical cancer biopsy 
specimens are found to be positive for HPV DNA. Both genotypes HPV16 and 
HPV18 are together responsible for 70% of cervical carcinomas. IFNs are an 
important part of the host defense against viral infection. Numerous previous 
studies have reported that IFNβ can induce the IRF7 expression through the 
JAK-STAT signaling pathway. It has been proposed that oncoproteins of high-
risk HPV can suppress type I IFN signaling.  
The mechanisms by which HPV can modify the cellular response to the 
treatment with cytokines such as TNFα and IFNβ have been extensively studied. 
In this study we examined the possible response of HPV-transformed (non-
malignant as well as malignant cells) and normal human keratinocytes to the 
cytokines TNFα and IFNβ. Major interest was to explore differences in 
expression of the transcription factor IRF7. Quantitative RT-PCR was done to 
investigate the expression of four genes comprising IRF7, Mx1 as a further IFNβ-
responsive gene, CCL20 as a further TNFα-responsive gene and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as a house keeping gene. 
We found that TNFα has limited ability to induce IRF7 expression in HPV-
transformed and normal human keratinocytes. This induction is in some cases of 
HPV18-transformed keratinocytes stronger than in HPV-negative keratinocytes. 
In addition, our data show that IRF7 expression induced by exogenous IFNβ is 
retained in most HPV-positive malignant and non-malignant keratinocytes. 
Except HeLa cells, TNFα and IFNβ induce synergistically IRF7 expression in 
HPV-negative and HPV-transformed keratinocytes. 
The present work demonstrates that the exogenous IFNβ signaling leading to 
induction of Mx1 expression and TNFα signaling leading to induction of CCL20 
are not disturbed in HPV-transformed and normal human keratinocytes. 
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Thus, HPV16 and HPV18 may have no negative effects on the response of 
mucosal human keratinocytes to the treatment with TNFα and/or IFNβ. 
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2. Zusammenfassung 
Eine persistierende Infektion mit Hochrisiko HPV stellt den wichtigsten 
ätiologischen Faktor für die Entstehung eines Zervixkarzinoms dar. In über 90% 
von zervikalen Gewebeproben kann HPV-DNA nachgewiesen werden. Die 
beiden Genotypen HPV16 und HPV18 sind zusammengenommen für 70% der 
Zervixkarzinome verantwortlich. Bei der Abwehrreaktion des Wirtsorganismus 
gegen virale Infektionen spielen Interferone eine wichtige Rolle. Zahlreiche 
frühere Studien konnten zeigen, dass IFNβ über den JAK-STAT Signalweg die 
Expression von IRF7 induzieren kann. Es wird vermutet, dass der Typ I IFN 
Signalweg durch Onkoproteine von Hochrisiko HPV unterdrückt werden kann. 
Der Mechanismus durch den HPV die zelluläre Reaktion nach Behandlung mit 
Zytokinen wie TNFα und IFNβ modifizieren können, ist intensiv untersucht 
worden. 
In dieser Arbeit wurde die mögliche Reaktion von HPV-transformierten (nicht-
malignen wie auch malignen Zellen) und normalen humanen Keratinozyten auf 
die Zytokine TNFα und IFNβ untersucht. Insbesondere sollten Unterschiede in 
der Expression des Transkriptionsfaktors IRF7 untersucht werden. Die 
Expression von den folgenden vier Genen, IRF7, Mx1 als ein weiteres IFNβ 
responsibles Gen, CCL20 als ein weiteres TNFα responsibles Gen sowie das 
Haushaltsgen Glycerinaldehyd-3-phosphat-Dehydrogenase (GAPDH) wurde mit 
Hilfe von quantitativer RT-PCR untersucht. 
Es zeigte sich, dass die Expression von IRF7 in HPV-transformierten und 
normalen humanen Keratinozyten durch TNFα nur begrenzt induziert werden 
kann. Diese Induktion ist in HPV18-transformierten Keratinozyten in manchen 
Fällen stärker als in HPV-negativen Keratinozyten. 
Weiterhin zeigen unsere Daten, dass die durch exogenes IFNβ induzierte 
Expression von IRF7 in den meisten HPV-positiven malignen und nicht malignen 
Keratinozyten beibehalten ist. Außer in HeLa Zellen lässt sich für TNFα und IFNβ 
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eine synergistische Induktion der Expression von IRF7 in HPV-negativen und 
HPV-transformierten Keratinozyten nachweisen. 
Die vorliegende Arbeit zeigt, dass die exogene IFNβ Signaltransduktion, die zu 
einer Induktion der Expression von Mx1 führt und die TNFα Signaltransduktion, 
die zu einer Induktion von CCL20 führt, in HPV-transformierten und normalen 
humanen Keratinozyten nicht gestört ist. 
Somit üben HPV16 und HPV18 vermutlich keinen negativen Effekt auf die 
Reaktion von mukosalen humanen Keratinozyten nach Behandlung mit TNFα 
und/oder IFNβ aus. 
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3. Glossary 
 
BSA Bovines Serum Albumin 
C4 I HPV18-positive human cervical carcinoma cell line 
CaSki HPV16-positive human cervical carcinoma cell line 
CBP CREP-binding protein 
CCL20 CC chemokine ligand 20 
cDNA Complementary deoxyribonucleic acid 
CIN cervical intraepithelial neoplasia 
CO2 Carbon dioxide 
Ct Threshold cycle 
DEPC Diethylpyrocarbonate 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleolide triphosphate 
DMEM Dulbecco s modified eagle medium 
DMSO Dimethylsulfoxid 
Ds Double-strand 
DTT Dithiothreitol 
E Real-Time PCR efficiency 
E1/2/4/5/6/7 Early proteins of HPV 
EBV Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid 
et al And others 
EXLN Primary exocervix keratinocytes 
FCS Fetal calf serum 
Fig Figure 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Hela  HPV18-positive human adenocarcinoma cell line 
HPK1A human foreskin keratinocytes immortalized with HPV16 
HPV Human papillomavirus 
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HPV16 HPV type 16 
HPV18 HPV type 18 
Hu Human 
IFN Interferon  
IFNβ Interferon beta 
IL Interleukin 
IRF  Interferon regulatory factor 
ISGs Interferon-stimulated genes 
ISGF3 Interferon-stimulated gene factor 3 
ISRE Interferon-stimulated response element 
JAK Janus kinase 
K51 human foreskin keratinocytes immortalized with HPV18 
KBM Keratinocyte cell basal medium 
L Late proteins of HPV 
LARC Liver and activation-regulated chemokine 
LPS Lipopolysaccaride 
M Milli 
M Molar 
Mg Milligram 
MgCl2 Magnesium chloride 
MIP-3α Macrophage inflammatory human protein-3 alpha 
Ml Milliliter 
mM Millimolar  
mRNA Messenger ribonucleic acid 
Mx1 Interferon-induced GTP-binding protein 
MyD88 Myeloid differentiation factor 88  
NFK13 Primary foreskin keratinocytes 
NF-kB Nuclear factor kB 
ORF Open-reading frame 
PAMPs Pathogen-associated molecular patterns 
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PBL Peripheral blood lymphocytes 
PBS Phosphate-buffered salt solution 
PCR Polymerase chain reaction 
P48 Protein 48 
P53 Protein 53 
P56 Protein 56 
P107 Protein 107 
P130 Protein 130 
P300 Protein 300 
R Reporter 
Rb Retinoblastoma 
RNA Ribonucleic acid 
Rpm Revolution per minute 
RT Room temperature 
RT-PCR Real-time polymerase chain reaction 
SW756 HPV18-positive cells of a differentiated cervical squamous cell 
carcinoma 
STAT Signal transducer and activator of transcription 
Q Quencher 
qPCR Quantitive polymerase chain reaction 
TE-SS Tris-EDTA salmon sperm 
Th T helper 
TIR Toll-interleukin-1 receptor 
TLR Toll-like receptor 
TNFα Tumor necrosis factor alpha  
TNFR Tumor necrosis factor alpha receptor 
TPA Phorbol ester 
TRIF Tir-domain-containing adaptor protein inducing IFNβ 
Tris Tris(-hydroxymethyl-) aminomethane 
Tyk-2 Tyrosine kinase 2 
X 
 
UPL Universal ProbeLibrary 
UV Ultraviolet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
4. Introduction 
4.1 Human papillomaviruses (HPVs) 
Human papillomaviruses (HPVs) are small double-stranded DNA viruses, which 
are classified into cutaneous and mucosal types according to their target tissue.  
The cutaneous types infect the squamous epithelia of skin, while the mucosal 
ones infect mucosal epithelia in the genital tract and oropharynx causing a 
variety of clinical outcomes and most notably cervical cancer (Zur Hausen, 
1999). 
Persistent high-risk HPV infection is the major aetiological factor for the 
development of cervical cancer, since over 99% of the cervical cancer biopsy 
specimens are found to be positive for HPV DNA (Zur Hausen, 1990; Melbye et 
al, 2002; Zur Hausen, 1996; Walboomers et al, 1999).  
Until now, there are more than 100 types of HPVs, but one-third of them target 
specifically the genital tract epithelium transmitted through sexual contact (Kjaer 
et al, 2001; Zur Hausen, 2002). The genital types of HPV are categorized into 
two groups according to their oncogenic potential: high-risk HPVs, which can 
induce malignant transformations, and low-risk HPVs, which can cause benign 
genital warts. The high-risk group includes HPV16, HPV18, HPV33, HPV31, and 
HPV45, whereas the most frequent types in the low-risk HPVs category are 
HPV6 and HPV11 (Zur Hausen, 2002). 
Infection with HPVs first causes low-grade lesions called cervical intraepithelial 
neoplasia grade 1 (CIN 1), which are mostly eliminated in 1-2 years. In a minority 
of patients the viruses can persist for decades evading from the immune system. 
In cases of oncogenic HPV,  the low-grade intraepithelial neoplasia (CIN 1) can 
consequently evolve to high-grade intraepithelial neoplasia and finally to cervical 
cancer (Ho GY et al, 1998; Jenson et al, 1991;Höpfl et al, 2000; Zur Hausen, 
1996). Cervical cancer is the 3-4 most prevalent cancer in women worldwide, 
where 470,000 new cases are annually recorded (Jemal et al, 2011).  
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What is more, HPVs can also cause other cancers, where it has been found that 
close to 93% of anal cancers in USA and up to 25-30% of oropharyngeal 
carcinoma are associated with human papillomaviruses (Joseph et al, 2008; Zur 
Hausen, 2000; Herrero et al, 2003). Moreover, these viruses have been identified 
in penile, vulvar, esophageal and skin carcinoma (Melbye et al, 2002; Zur 
Hausen, 1996; Zur Hausen, 1990; Wieland et al, 2000; Syrjänen, 2002). 
HPVs are not the only risk factor for emergence of cancer, but a number of 
cofactors are probably additionally involved in carcinogenesis such as smoking, 
co-infection with human immunodeficiency virus, and immunosuppression (Lie 
AK, 2000; Kjellberg et al, 2000; Daling et al, 1996).  
4.1.1 The HPV proteins 
Genomes of mucosal HPVs contain 8 open-reading frames (ORFs), and the 
products of these genomes are classified into early and late proteins. The early 
proteins are expressed in the early phase of the virus life cycle in undifferentiated 
keratinocytes, and these proteins are E1, E2, E1^E4, E5, E6, and E7. On the 
other hand, the late proteins L1 and L2 are structural proteins, which are 
subsequently expressed in differentiated epithelial cells forming the icosahedral 
capsid of the virus (Longworth & Laimins, 2004).  
Upon viral infection the first viral genes to be expressed are E1 and E2 genomes, 
and their products E1 and E2 proteins initiate cooperatively the replication of 
DNA virus by recruiting the DNA-polymerase and accessory protein of the host 
cell (Conger et al, 1999). 
E1^E4 protein is thought to be able to induce collapse of the keratin network in 
keratinocytes and may play a role in initiating the differentiation-dependant phase 
(Doorbar et al, 1991). 
E5 protein is expressed early in the productive phase of the viral life cycle 
(Fehrmann et al, 2003; Genther et al, 2003). 
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High-risk HPVE6 is an oncoprotein, which has significant effects on the infected 
epithelial cells. It can cause immortalization and malignant transformation due to 
its binding to p53, its degradation and/or blocking p53 function. (Huibregste & 
Beaudenon, 1996; Huibregste et al, 1991; Scheffner et al, 1990). p53 is a tumor 
suppressor protein, which is activated upon DNA damage inducing cell cycle 
arrest and apoptosis (Lechner & Laimins, 1994; Ko & Prives, 1996). Furthermore, 
E6 can indirectly reduce p53 activity by forming a complex with its co-activator 
p300/CBP. p300/CBP is a histone acetyltranferase which activates p53 by 
acetylation. As a result of this complex formation the acetylation of p53 is 
suppressed and finally p53 activity is downregulated (Zimmermann et al, 1999; 
Patel et al; 1999). 
It is important to notice that E6 oncoprotein is alone insufficient for efficient 
immortalization and malignant transformation in infected cells, but it needs the 
cooperation of E7 oncoprotein (Hawley-Nelson et al, 1989; Münger et al 1989a). 
E7 interacts with members of the retinoblastoma (Rb) family of tumor suppressor 
proteins. p107, p130 and Rb regulate cell cycle progression. The association of 
E7 with Rb family abrogates function which is essential for the productive stage 
of the viral life cycle (Münger et al, 1989b; Dyson et al, 1989; Classon & Dyson, 
2001; Berezutskaya et al, 1997; Münger et al, 1992) (Fig. 1). 
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Figure 1 Organization of HPV genome.  The early region expresses the early proteins including 
E1, E2, E4, E5, E6, and E7. The late region of the genome encodes capsid proteins comprising 
L1 and L2. LCR is a control region. (Adapted from Lie & Kristensen 2008). 
4.1.2 HPV life cycle 
HPVs are non-enveloped viruses that infect keratinocytes of the stratified 
epithelium and replicate in their nuclei. Papillomaviruses can enter basal 
keratinocytes via a microtrauma in the epithelium. Upon the viral entrance into 
the basal cell, the virus is established in the host nucleus as an 
extrachromosomal episome replicating concurrently with the host cell in average 
of 20-100 copies of viral DNA per cell. The virus does not encode a DNA 
polymerase and other replication factors, so that it has to use those of the host 
cell (Longworth & Laimins 2004; Fermann & Laimins, 2003). The recruitment of 
the cellular replication machinery for the virus replication is due to the function of 
both E1 and E2 viral proteins, which are the first viral proteins to be expressed 
(Conger et al, 1999). 
The productive life cycle of these viruses is strongly restricted to the 
differentiated keratinocytes (Longworth & Laimins, 2004). The expression of the 
late viral proteins is limited to the differentiated cells (Laimins LA, 1993). In 
5 
 
normal keratinocytes a basal cell divides into two daughter cells, one of them 
remains in the basal layer and serves as a reservoir for later cellular divisions, 
and the other migrates towards the suprabasal layers undergoing differentiation. 
For differentiation, keratinocytes have to leave the cell cycle. In contrast, in 
keratinocytes infected with high-risk HPVs the viral oncoproteins can induce re-
entry into the cell cycle even in differentiating layers.  
The oncoproteins E6 and E7 interfere with the host cell proteins, p53 and (Rb) 
family members, respectively, and thereby promote vegetative viral replication in 
the suprabasal strata of the epithelium to thousands of copies per cell (Cheng et 
al, 1995; Flores et al, 2000). In the upper layers, the late proteins L1 and L2 of 
the virus are produced and the mature infectious virions are assembled. Mature 
viruses are released by shedding of the more differentiated epithelial cells (Fig. 
2) (Longworth & Laimins 2004). 
It has been demonstrated that the viral genome exists as extrachromosomal 
episome in low-grade intraepithelial neoplasia, while it is found often integrated 
into the genome of the host cell in the cancerous specimens. This integration of 
the viral gene into the host keratinocyte sequences takes place within the E2 
ORF. Therefore the suppressive effect of E2 protein is lost leading to higher 
expression of E6 and E7 proteins (Jeon et al, 1995; Choo et al, 1987; Tonon et 
al, 2001). 
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Figure 2 Diagram showing normal epithelium (left) and human papillomavirus (HPV) infected 
epithelium (right). As the HPV infected cell of the basal membrane replicates, the DNA virus also 
replicates with it as extrachromosomal DNA. In the upper layers the late genes are expressed 
and the viral DNA is encased, after that the virions are released into the environment with the 
discarded epithelial cells. (Modified from Moody & Laimins, 2010). 
4.2 The role of interferon in the immune system 
Interferon (IFN) was identified as an agent produced from influenza virus 
infected-cells and this agent was able to protect other cells from viral infection. 
IFNs are a family of cytokines which possess various biological functions such as 
a characteristic antiviral activity, regulation of cell growth, and immunomodulatory 
activity (Pestka et al, 1987; Isaacs & Lindenmann, 1957; Lindenmann, 1982; 
Tanaka et al, 1998). IFNs have a decisive role in the host defense against viral 
infection either in autocrine manner, or in paracrine manner by establishment of 
antiviral state in uninfected cells (Tanaka et al, 1998). IFNs can interfere with the 
replication and transcription of many viruses (Vilcek, 2006). Interferons can be 
grouped into three types, type I IFNs, type II IFNs and type III IFNs. Type I IFNs 
are known as viral IFNs according to their critical role in the early host defense 
against viral infection, and this type of IFNs comprise IFNα, IFNβ, IFNω, IFNε 
and IFNκ, while IFNγ is the only member in type II IFNs. There is only one IFNγ 
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gene and also one IFNβ gene, but there are 13 IFNα genes. The last identified 
interferons IFNλ1, IFNλ2, and IFNλ3 are classified as type III IFNs, and it has 
been found that these new interferons are produced in virally infected cells 
(Takaoka & Yanai, 2006). IFNα and IFNβ, the best characterized type I IFNs, can 
be produced from several types of cells  in response to viral and other microbial 
infections, while only special immune cells including natural killer (NK) cells, 
CD4+ T helper 1 (Th1) cells and CD8
+ cytotoxic T cells are capable of IFNγ 
excretion. IFNs demonstrate their pleiotropic properties by binding to specific cell 
surface receptors and this binding activates the expression of more than 30 
different cellular proteins through the Janus kinase/signal transducers and 
activators of transcription JAK-STAT signaling pathway, whose components 
belong to two types of transcription factors. The first is termed as Janus kinase 
family (JAK) and comprises Jak-1, Jak-2 and Tyk-2 kinases, whereas the second 
is the signal transducer and activator of transcription family (STAT). Both, Stat1 
and Stat2, are essential player in the IFN-signaling pathways. Upon the 
treatment of the cell with IFN α/β, Jak-1 and Tyk-2 kinase activate Stat1 which in 
turn forms heterodimer with Stat2, and then the Stat1-Stat2 heterodimers 
translocate to the nucleus and together with p48 form interferon stimulated gene 
factor 3 (ISGF3), complex causing the induction of IFN-inducible genes. On the 
other hand, when the cell is exposed to IFNγ, Jak-1 and Jak-2 are activated and 
consequently phosphorylate Stat1, which undergoes homodimerization and then 
nuclear translocation leading to induction of gene expression (Fig. 3) (Pestka et 
al, 1997; Silvennoinen et al, 1993; Katze et al; 2002; Velazquez et al, 1992; 
Darnell et al, 1994). 
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Figure 3 Diagram showing the induction of Jak-Stat pathway by IFNs. IFNα/β exhibit their 
actions by binding to their specific receptors which leads to activation of Jak1 and Tyk2 of the 
janus kinase family (Jak) resulting in phosphorylation of Stat1 and Stat2. Stat1 and Stat2 
heterodimer, then translocate into the nucleus and bind to protein 48 (IRF9) forming the ISGF3 
complex on the interferon response element (ISRE). On the other hand, the association of IFNγ 
with its receptor activates Jak1 and Jak2, which in turn activates Stat1. Activated Stat1 
undergoes homodimerization and then nuclear translocation which leads to binding on IFNγ-
activated sequence (GAS). (Koromilas et al, 2001).  
4.3 The IRF family 
Interferon regulatory factors (IRFs) are group of nine transcription factor proteins 
(IRF-1 to IRF-9) inducible by IFNs. They exhibit diverse biological functions 
comprising apoptosis, immune response, cell growth regulation, oncogenesis 
and host defense (Romieu-Mourez et al, 2006; Sato et al, 2000; Pitha et al, 1998; 
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Honda et al, 2005; Nakamura et al, 2001; Nguyen et al, 1997). It has been 
elucidated that the two members IRF3 and IRF7 of this family are essential 
regulators of the induction of IFNα/β as an innate immune response to viral 
infection (Sato et al, 2000; Wathelet et al, 1998). Interferon regulatory factor 3 
(IRF3) is constitutively expressed in the cytosol of cells in a latent form, but viral 
infection triggers the phosphorylation of IRF3, dimerzation and nuclear 
translocation. This in turn provokes IFNα4 and IFNβ production. IRF3 has a 
stronger stimulatory impact on IFNβ genes than on IFNα genes (Juang et al, 
1998; Yoneyama et al, 1998). 
Interferon regulatory factor 7 (IRF7) is mapped in human to chromosome 11, and 
it has short half-life (only 0.5-1 h). The first detection of IRF7 was in the context 
of research on Epstein-Barr virus (EBV) (Zhang & Pagano, 1997; Zhang & 
Pagano, 2002). 
IRF7 is expressed in the spleen, thymus and peripheral blood lymphocytes 
(PBL), but it is also found at low levels in all tissues (Zhang & Pagano, 1997; Au 
et al, 1998). Many factors can activate the expression of IRF7 such as IFNα, 
IFNβ, viral infection, lipopolysaccaride (LPS), DNA-damaging agents like ultra-
violate light (UV), in addition to chemical substances like sodium butyrate and 
phorbol ester (i.e. TPA) (Sato et al, 2000; Lin et al, 2000; Zhang & Pagano; 
2002). 
Both IRF3 and IRF7 are key regulators of IFN-mediated responses to viral 
infection. Two distinct phases in interferon induction can be distinguished 
achieving a robust innate immune defense against viral infection (Au et al, 1998; 
Honda et al, 2005; Sato et al; 1998; Kumar & Korutla 1995; Kimura et al 1996; 
Marie et al, 1998).  
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4.4 Toll-like receptors (TLRs) 
Toll-like receptors (TLRs) are type I transmembrane proteins that have key roles 
in the innate and also adaptive immune response. They recognize pathogen-
associated molecular patterns (PAMPs), which may be lipids, lipoproteins, 
proteins and nucleic acids drawn from  a large spectrum of microbes including 
viruses (Akira et al, 2001; Akira et al, 2006). Up to now, they are grouped into 
two subgroups according to their cellular localization and related PAMP. TLR1, 
TLR2, TLR4, TLR5, TLR6 and TLR11 belong to the first group, which exists on 
the cell surface and recognizes membrane parts of the microbes such as lipids, 
proteins and lipoproteins. Moreover, the second group includes TLR3, TLR7, 
TLR8 and TLR9 which locate within the cells and recognize nucleic acids (Kawai 
& Akira, 2010). Each TLR consists of leucine-rich domain, that binds to the 
pathogen, transmembrane domain, and intracellular toll-interleukin 1 (IL1) 
receptor (TIR)-domain, whose role is critical in the activation of signal 
transduction following either myeloid differentiation factor 88 (MyD88)-dependent 
pathway or TIR-domain-containing adapter-inducing interferon beta (TRIF)-
dependent pathway activation. As a result, the activation of both pathways leads 
to production of inflammatory cytokines and type I interferon through the 
activation of nuclear transcription factor κB (NF-κB) and interferon regulatory 
factors IRF7 or IRF3. These TLR signaling serves as an antiviral way of the host 
cell to fight against viral infection (Gay & Gangloff, 2007; Jin & Lee, 2008; Akira 
et al, 2006; Kawai & Akira, 2009). Furthermore, both figure (4) and figure (5) 
respectively, show how cell surface TLRs and intracellular TLRs recognize the 
PAMPs that finally cause the production of an inflammatory cytokines and type I 
IFN by recruiting MyD88 or TRIF. 
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Figure 4 PAMP recognition by cell surface TLRs. TLR4 recognizes LPS inducing signal 
transduction through either MyD88-dependent pathway, or TRIF-dependent pathway, which leads 
consequently to induction of type I IFN and inflammatory cytokines. TLR2-TLR1, TLR2- TLR6 
heterodimers and TLR5 trigger induction of inflammatory cytokines by recruiting the MyD88-
dependent pathway (Kawai & Akira, 2010). 
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Figure 5 PAMP recognition by intracellular TLRs. TLR3 recognizes dsRNA derived from 
viruses and then triggers the induction of type I IFN and inflammatory cytokines through TRIF-
dependent pathway. TLR7 recognizes ssRNA activating the production of type I IFN and 
inflammatory cytokines through the MyD88-dependent pathway. TLR9 recognizes DNA extracted 
from viruses, and then activates the MyD88-dependent pathway resulting in production of 
inflammatory cytokines and type I IFN by triggering of NFκB and IRF7, respectively (Kawai & 
Akira, 2010). 
4.5 Tumor necrosis factor alpha TNFα 
Tumor necrosis factor alpha TNFα is a proinflammatory cytokine produced upon 
infection by a wide range of cells such as macrophages, CD4+ T-lymphocytes, 
CD8+ T-lymphocytes, B-lymphocytes, NK cells and neutrophils. Inflammation, 
induction of immune responses and host defense belong to the various functions 
of TNFα, which achieves these functions by binding specifically to TNF receptors, 
which belong to the TNF receptor superfamily (Mak & Yeh, 2002; Idriss & 
Naismith, 2000). As a consequence of the binding of TNFα to its receptors many 
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signaling pathways are activated particularly the NF-κB pathway inducing a 
number of transcription factors such as IRF7 (Lu et al, 2002). 
4.6 Human papillomavirus (HPV) and interferon (IFN) 
Human papillomavirus proteins interfere with the cellular response to IFNs by 
multiple mechanisms. The E6 oncoprotein targets many components of the IFN-
signaling pathway, where it is known now that E6 binds to Tyk2 kinase blocking 
the induction of the Jak-Stat pathway by interferon (Li et al, 1999). Moreover, it 
has been reported that E6 protein interacts with IRF3 (Ronco et al, 1998; 
Zimmermann et al, 1999; Patel et al; 1999). In addition to E6 oncoprotein, E7 
oncoprotein can also mediate the IFN-signaling pathway either by binding to 
IRF1 and blocking its function (Park et al, 2000; Perea et al, 2000), or by binding 
to p48 which is considered a pivotal part of the ISGF3 complex causing 
suppression of the IFN-inducible genes. It has been found that the response to 
the IFN-treatment is correlated with the levels of E7 oncoprotein (Barnard & 
McMillan, 1999). Furthermore, Chang and Laimins (2000) have reported that the 
HPV31 proteins target Stat1 causing the disruption of its decisive role in 
mediating the response to IFN, and then resulting in repression of IFN-inducible 
genes. The previous way is utilized by HPV in modulating the IFN-signal pathway 
and may serve as a strategy to evade from the immune defense and persist.  
4.7 IFN therapy 
IFN have been variously used for therapy of HPV-induced diseases, however 
with mixed results. Genital warts caused by low-risk types of HPV have been 
eliminated after the IFN application in some studies. In contrast, the responses of 
lesions triggered by high-risk types of HPV have varied even to a higher degree. 
More important for IFN-responsiveness was the integration status of the viral 
DNA in the nucleus of the host cell. Whereas lesions harboring episomal viral 
DNA have been cleared, more efficient lesions with integrated viral DNA have 
been more resistant to the treatment with IFN (Beglin et al, 2009; Koromilas et al, 
2001). Terenzi and others (2008) have found that the interferon-inducible protein 
56 (p56) plays the main role in the response to IFN-treatment by binding to the 
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viral protein E1 which is a key factor in the viral DNA replication. The interaction 
of p56 with the E1 protein leads to sequestering of the E1 protein from the 
nucleus to the cytoplasm resulting in inactivation. Accordingly the viral DNA 
replication is inhibited.  
4.8 Interferon-induced GTP-binding protein Mx1 
Mx1 gene is one of the interferon-stimulated genes (ISGs) firstly characterized in 
mice as an antiviral factor against influenza virus infection (Aebi et al, 1989; 
Haller et al, 1998; Horisberger et al, 1983; Lindenmann, 1962). Haller and Kochs 
(2002) have demonstrated that Mx1 can repress the replication of certain RNA 
viruses. Mx1 protein exists normally in the cytoplasm of the cell in undetectable 
levels, but after exposure to type I IFN, Mx1 production is stimulated reaching up 
to 1% of the cytosolic proteins, whereas weak activation of Mx1 gene expression 
has been noticed by IFNγ, and type III IFN (Holzinger et al, 2007; Aebi et al, 
1989; Horisberger, 1992). On the other hand, while IFNα and IFNβ are 
considered as potent inducers of Mx1, Simon and others (1991) have 
demonstrated that Mx1 gene expression does not respond to the stimulation with 
tumor necrosis factor alpha (TNFα). 
As a result of the previous considerations, Mx1 gene expression is commonly 
used as a unique marker for the detection of the various biological actions of IFN 
in the context of the IFN-therapy or during viral infection. Hence Mx1 can serve 
as a positive control to the induction by interferon. 
4.9 CC chemokine ligand 20 (CCL20) 
CCL20 is a chemokine known previously as macrophage inflammatory human 
protein-3 alpha (MIP-3α) or liver and activation-regulated chemokine (LARC). 
CCL20 is constitutively expressed at low levels in the cell and inducible by poly 
I:C (dsRNA) and many stimuli like lipopolysaccharides (LPS). Sperling and 
others (2012) have demonstrated novel CCL20 induction pathway by CCAAT-
enhancer-binding proteins C/EBPβ in normal human keratinocytes. IL-1β and 
TNFα have been established as strong inducers of the CCL20 induction through 
activation of the NF-κB signal pathway, while IFNγ has no effect on CCL20 
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production (Reibman et al, 2002; Nakayama et al, 2001; Fujiie et al, 2001; 
Hosokawa et al, 2005; Schutyse et al, 2000; Tohyama et al, 2001). Therefore, 
CCL20 can be used in gene expression studies as a reliable marker for the TNFα 
bioactivities. 
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5. Aim of the study 
More than 99% of cervical carcinomas are positive for HPV DNA. The genital 
high-risk types HPV16 and HPV18 are account for more than 70% of cervical 
cancer.  Interferons represent an important part of the host defense against viral 
infection. In HPV-mediated skin carcinogenesis, IRF7 binds to viral DNA and 
increases the activity of the late promoter of a cutaneous high-risk HPV8 
however, the role of IRF7 in genital carcinogenesis is so far unknown. 
In this study we examined the expression of the transcription factor IRF7 after 
TNFα or IFNβ stimulation. We focused on the differences between normal HPV-
negative keratinocytes in comparison to HPV16- or HPV18-infected non-
malignant as well as malignant cells.  
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6. Material and Methods 
6.1 Material 
6.1.1 Eukaryotic cell lines  
C4-I: HPV18-positive human cervical carcinoma cell line. 
CaSki: HPV16-positive human cervical carcinoma cell line. 
HeLa: HPV18-positive human adenocarcinoma cell line.  
HPK1A: human foreskin keratinocytes immortalized with HPV16. Contains 2-3 
integrated HPV16 genomes. 
K51: human foreskin keratinocytes immortalized with HPV18.  
SW756: HPV18-positive cells of a differentiated cervical squamous cell 
carcinoma. 
EXLNp5: primary exocervical normal human keratinocytes (HPV negative) in 
passage 5.  
NFK13p3: primary normal human foreskin keratinocytes (HPV negative) in 
passage 3.  
6.1.2 Culture media and reagents for cell culture  
Media and additives 
Keratinocyte Basal medium  
KBM-Gold medium                                                      
Lonza, Köln  
Trypsin/EDTA, 0.25mg/ml  Lonza, Köln  
Dulbeccoʹs modified eagle medium 
(DMEM) 
PAA, Pasching 
Fetal calf serum (FCS) PAA, Pasching 
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Penicillin, Streptomycin  
          Penicillin, 10.000 Units/ml 
          Streptomycin, 10 mg/ml 
PAA, Pasching 
Sodium-pyruvate, 11g/l PAA, Pasching 
Dimethylsulfoxid (DMSO) Sigma-Aldrich, Steinheim 
PBS PAA, Pasching 
Complete medium for NFK and EXLN cells 
KBM-Gold medium with KGM-Gold Single Quots  
Complete medium for the other cells 
DMEM with 10% FCS, 1% sodium-pyruvate and 1% Penicillin/Streptomycin 
Freezing medium 
90% FCS with 10% DMSO  
6.1.3 Reagent system 
6.1.3.1 RNA isolation 
QIAschredder                                   QIAGEN, Hilden 
RNeasy kit                                       QIAGEN, Hilden 
RNase-free DNAse set                     QIAGEN, Hilden 
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6.1.3.2 cDNA synthesis and RT-PCR 
The super-script II system from Invitrogen Corporation, Karlsruhe, was used for 
cDNA synthesis. In addition, for the quantitative Real-Time PCR a kit FastStart 
Taq DNA polymerase, dNTPack 5U/μl from company of Roche, Mannheim was 
used. 
This kit included: 
                             FastStart Taq DNA polymerase, 5U/μl 
                             PCR buffer, 10 x concentrated without MgCl2 
                             MgCl2, 25 mM       
                             Nucleotid mix (dATP, dGTP, dCTP, dTTP) 
For the quantification of cDNA special fluorescent probes from the human 
Universal ProbeLibrary (UPL) from Roche Company, Mannheim were used. 
6.1.4 Cytokines for stimulation 
Betaferon IFNβ-1b                        Schering 
250 µg/ml          
TNFα 106 U/ml                               Boehringer 
6.1.5 Chemicals 
Agarose Lonza, Köln 
β-Mercaptoethanol  Sigma-Aldrich, Steinheim 
Bovine Serum Albumin (BSA)  Fermentas, St. Leon-Roth 
Chloroform Roth, Karlsruhe 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Steinheim 
Ethanol Roth, Karlsruhe 
20 
 
Ethylenediaminetetraacetic acid (EDTA) PAA, Pasching 
Ethidiumbromide Sigma-Aldrich, Steinheim 
Formaldehyde Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
Nucleotide (dNTPs)  Invitrogen, Karlsruhe 
Salmon sperm DNA  Invitrogen, Karlsruhe 
Tris-EDTA buffer solution  
(TE-buffer) 
BioUltra Fluka Analytical 
Trizol reagent  Invitrogen, Karlsruhe 
Tween 20  Serva, Heidelberg 
 
6.1.6 Oligonucleotide for real time PCR 
The real time PCRs were designed with the Universal ProbeLibrary (UPL) 
Program of Roche Company, Mannheim. The oligonucleotides were purchased 
from the company Sigma-Aldrich, Steinheim. 
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Table 1 Primers, MgCl2 concentration and probe number used for RT-PCR of GAPDH. 
GAPDH 
Sense 
and 
antisense primer 
5ʹ-CTGACTTCAACAGCGACACC-3ʹ 
 
5ʹ-TGCTCTAGCCAAATTCGTTGT-3ʹ 
MgCl2 
Concentration 2mM 
No. of UPL probe 25 
 
Table 2 Primers, MgCl2 concentration and probe number used for RT-PCR of IRF7. 
IRF7 
Sense 
and 
antisense primer 
5ʹ-TCGACTTCAGAGTCTTCTTCCA-3ʹ 
 
5ʹ-CGAAGCCCAGGTAGATGGTA-3ʹ 
MgCl2 
Concentration 
4mM 
No. of UPL probe 31 
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Table 3 Primers, MgCl2 concentration and probe number used for RT-PCR of Mx1. 
Mx1 
Sense 
and 
antisense primer 
5ʹ-CTGACCTTGCCTCTCCACTT-3ʹ 
 
5ʹ-ACTGTCAGGAGTTGCCCTTC-3ʹ 
MgCl2 
Concentration 
5mM 
No. of UPL probe 34 
 
Table 4 Primers, MgCl2 concentration and probe number used for RT-PCR of CCL20. 
CCL20 
Sense 
and 
antisense primer 
5ʹ-GCAGTCAAAGTTGCTTGCTTC-3ʹ 
 
5ʹ-GCTGCTTTGATGTCAGTGCT-3ʹ 
MgCl2 
Concentration 
4mM 
No. of UPL probe 39 
 
6.1.7 Plastic ware 
Plastic ware was used from the company of Greiner, Frickenhausen; Nunc, 
Wiesbaden; Sarstedt, Nümbrecht; TPP, Trasadingen, Schweiz and VWR, 
Darmstadt.  
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6.1.8 Equipments 
Centrifuges Heraeus Megafuge 1,0 R  
Heraeus Picofuge  
Sigma-Aldrich 202 MK  
UV-Spectrophotometer NanoDrop model 2000C, Thermo scientific 
Microscope Leica DMI600 B 
Neubauer counting chamber               NeoLab, Heidelberg 
Real-Time PCR Cycler                        LightCycler 480, company Roche Mannheim 
UV-Gel documentation BioRad ChemiDoc XRS+ 
6.1.9 Computer programs and internet websites 
Design of primer PrimerBlast of  NC                                                           
(www.ncbi.nlm.nih.gov/tools/primer-blast/) 
Design of primers for qRT-PCR Universal ProbeLibrary of the company 
Roche,Mannheim 
(www.rocheappliedscience.com 
/sis/rtpcr/upl/ezhome.html) 
Establishment of the diagrams and 
statistics 
Microsoft Excel 2007 
Literature                    Pubmed, hompage of NCBI 
(www.ncbi.nlm.nih.gov/pubmed) 
Establishment of the text Microsoft Word 2007 
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6.2 Methods 
6.2.1 Cell culture 
6.2.1.1 Cultivation of the cells 
The cells were cultivated in DMEM complete medium at 37°C with 5% CO2. To 
harvest the cells, medium was discarded, the cells were washed with 2ml PBS, 
4ml Trypsin/EDTA was added and the cells were incubated for 5 minutes at 
37°C. The detaching of the cells was controlled by using a microscope (Leica 
DMI600 B). 
The enzymatic activity of Trypsin was stopped by adding 6ml DMEM complete 
medium. The cells were seeded in the desired ratio according to the cell density 
and the growth rate. 
6.2.1.2 Cell number determination 
To calculate the cell number, the medium was discarded and the cells were 
washed with 2ml Trypsin/EDTA and then incubated with 4ml Trypsin/EDTA for 5 
minutes at 5% CO2. The detaching of the cells was checked up by microscope. 
6ml DMEM complete medium was added to stop the activity of Trypsin and then 
centrifuged for 5 minutes at 1200 rpm at room temperature. The supernatant was 
removed and the pellet was resuspended in 20ml DMEM complete medium. 
10µl Trypan blue was added to 10µl of the cell suspension in 1.5ml reaction tube. 
The cells were incubated for 2 minutes at room temperature and then 10µl were 
calculated in the Neubauer-chamber. 
By using microscope, the cells were counted in 4 large squares. The mean was 
calculated and the required number of the cells was calculated as the following: 
The required number = the calculated mean ×2×104 cells/ml 
                                                    (2 means the ratio of dilution)  
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6.2.1.3 Seeding of the cells 
1.5×106 cells were seeded in 6cm2 cell culture dishes, and finally the volume was 
completed to 3ml with DMEM complete medium. The cells were incubated 
overnight in 5% CO2 at 37°C. 
6.2.1.4 Seeding of the primary cells (NFK and EXLN) 
250 000 cells were seeded in 6 well cell culture dishes and then the volume was 
completed to 2ml with KBM-Gold medium with additives (Hydrocortisone 0.5 ml, 
Transferrin 0.5 ml, Epinephrine 0.25 ml, GA-1000 0.5ml, BPE 2.0 ml, rhEGF 0.5 
ml and insulin 0.5 ml). Trypsin/EDTA was used for detaching the cells, TNS for 
stopping this detaching and HEPES for washing the cells. The cells were 
incubated overnight in 5% CO2 at 37°C. 
6.2.1.5 Thawing of the cells 
The cryo-tubes with the cells were taken from -80°C storage and quickly thawed 
at 37°C. The cells were centrifuged in 4ml medium at 1200 rpm for 10 minutes at 
room temperature. The supernatant was discarded and the cells were 
resuspended in 4ml medium and transferred in 75 cm2 cell culture flask with 20ml 
medium. 
6.2.1.6 Freezing of the cells  
The cultivated cells were resuspended with 4ml freezing medium consisting of 
10% DMSO and 90% FCS. The cell suspension was aliquoted in cryo-tubes that 
are already on ice. The cryo-tubes were left at -80°C for few days, and then 
stored with liquid nitrogen. 
6.2.2 Stimulation of the cells 
Tumor necrosis factor alpha (TNFα), 1×106 U/ml, was diluted to 1×103 U/ml in 
DMEM medium without additives.  
Interferon beta (IFNβ), 8×106 U/ml, was diluted to 1×102 U/ml in DMEM medium 
without additives. 
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From the cells, which were incubated overnight, the medium was removed. Then 
2ml from the diluted TNFα and 2ml IFNβ were added to each dish. The dishes 
were incubated for 16 hours in 5% CO2 at 37°C. 
6.2.3 RNA-Isolation 
a) RNeasy Kit (Qiagen) 
Medium was completely removed from the culture dishes and the cells were 
washed with PBS. 
The cells attached to the bottom of the dishes were disrupted by adding 600µl 
RLT buffer and scraping with cell scraper. Lysate was directly pipetted into a 
Qiashredder spin columns placed on 2ml collection tubes and then centrifuged 
for 2 minutes at 11000 rpm by using Heraeus Picofuge centrifuge. Flow was 
mixed well with 600µl of 70% Ethanol. The mixture was applied including any 
precipitate that may have formed, to RNeasy mini columns placed on 2ml 
collection tubes and centrifuged for 15 seconds at 11000 rpm, so that the RNA 
bound to the membrane. Then the spin column membrane was washed with 
350µl RW1 buffer. Next, a 10µl DNase in 70µl RDD buffer was added to each 
column and incubated for 15 minutes at room temperature in order to remove the 
rests of DNA from the RNA. Washing was done three times: the first one was 
done with 350µl RW1 buffer, second with 500µl RPE buffer, and the last one with 
500µl RPE buffer. For elution, the RNeasy columns were transferred to a new 
1.5ml collection tube and then 50µl RNase free water was pipetted directly on the 
RNeasy silica gel membrane and afterwards centrifuged for 1 minute at 11000 
rpm. The concentration of the RNA was measured by NanoDrop model 2000C, 
Thermo scientific. 
b) Trizol/Phenol-Chloroform method (Invitrogen, Karlsruhe) 
The medium was discarded from the culture dishes and the cells were washed 
with PBS. 1ml Trizol was added and incubated for 5 minutes at room 
temperature then lysed by repeated pipetting. Lysate was flowed in 2ml reaction 
tube. 200µl Chloroform was added and the tubes were shaked strongly for 15 
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seconds by hands and incubated for 2-3 minutes at room temperature. The tubes 
were centrifuged for 15 minutes at 4ºC at 12000 rpm. The squamous phase was 
transferred to fresh tubes, 500µl Isopropyl was added and incubated for 10 
minutes at room temperature, then centrifuged for 10 minutes at 4ºC and 12000 
rpm. As a result, the RNA formed gel like pellet on sides and bottom of the tubes. 
The supernatant was removed and the pellet was washed with 1000µl of 70% 
Ethanol, then centrifuged, shortly dried and then lysed in 51µl EDTA 0.001M 
pH7, 6µl DNase buffer, 3µl RNase , and 2µl RNasin. This mixture was vortexed, 
centrifuged and incubated for 20 minutes in water bath at 37ºC, then for 15 
minutes in water bath at 70ºC. The concentration of RNA was measured by 
NanoDrop model 2000C, Thermo scientific. 
6.2.4 RNA-gel 
After isolating of RNA, an electrophoresis was done on an agarose gel to check 
the quality of RNA. Ethidium Bromide was used as a dye and UV-light was used 
for controlling. To prepare 1% gel, 0.5 agarose, 31ml DEPC water and 10ml of 5 
× RNA-running buffers were heated in the microwave and then 9ml formaldehyde 
was added. 1µg RNA was mixed with 5µl loading buffer which contained 
Ethidium Bromide, and then incubated for 15 minutes in water bath at 65ºC. The 
samples were loaded on the gel and electrophoresed for 90 minutes at 80 volt. A 
controlling with UV-light was done to estimate the quality of the RNA. 
When two distinct bands 18s and 28s RNA were visible; the RNA was intact (Fig. 
6). 
 
 
A) Intact RNA B) Degraded RNA  
Figure 6 Verification of isolated RNA on agarose gel. (A) Intact RNA (18s and 28s RNA), (B) 
degraded RNA. 
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6.2.5 cDNA synthesis 
The enzyme Reverse Transcriptase synthesized the DNA-strand from the RNA-
template by using the SuperScript II system of Invitrogen. 
The following components were pipetted: 
Component Amount 
Random primer 500µM  1 µl 
RNA 0.5 µg 
d NTPs 10mM 1µl 
Sterile water free of RNase to 12µl 
 
The mixture was heated to 65 ºC for 5 minutes in a water bath and chilled quickly 
on ice and then the following components were added: 
Component Amount 
5 x First-Strand Buffer 4µL 
0.1 M DTT 2µL 
 
The contents of the tube were mixed gently and incubated in water bath 42 ºC for 
2 minutes. After that, 1µl of Reverse Transcriptase enzyme was added then 
mixed gently by pipetting up and down. Next, the tubes were incubated in water 
bath at 42 ºC for 50 minutes and at 70 ºC for 15 minutes to inactivate the 
enzyme. A dilution 1:10 was done with sterile water free of RNase for RT-PCR. 
6.2.6 Real-time PCR (RT-PCR) 
Polymerase chain reaction (PCR) is an amplification of a specific DNA sequence 
by using primers which bind to the complementary sequences in the target DNA. 
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Consequently, a large number of copies of DNA may be obtained by doing 30-40 
cycles of 3 steps: 
a) Denaturing of the double-stranded DNA for 1 minute at about 95 ºC by 
disrupting the hydrogen bonds between the complementary bases. 
b) Annealing of the reverse and forward primers to the complementary DNA 
sequences for 45 seconds at about 50-60 ºC. The primers are only to start 
the amplification. 
c) Extending of the annealed primers by DNA polymerase, which reads from 
3ʹ to 5ʹ and adds the nucleotides from 5ʹ to 3ʹ, in presence of deoxy 
nucleoside triphosphates (dNTPs) for 2 minutes at about 70 ºC depending 
on the DNA polymerase used. 
There is an exponential increase of the number of the gene due to the copying 
both strands during PCR (Fig. 7). 
 
Figure 7 The three steps of PCR principle. The first step is denaturing of the double-stranded 
DNA for 1 minute at about 95 ºC. Secondly is annealing of the reverse and forward primers to the 
complementary DNA sequences for 45 seconds at about 50-60 ºC. Thirdly is extending of the 
annealed primers by DNA polymerase for 2 minutes at about 70 ºC. 
30 
 
Real-time PCR (RT-PCR) or quantitive PCR (qPCR) enables both detection and 
quantification of one or more specific sequences in the gene at every cycle by 
using fluorescent dyes which can be specific or non specific dyes. 
Non specific dye like SYBR green intercalates with any double-stranded DNA 
including non specific PCR products such as primer dimer, while a specific dye 
like TaqMan binds only to the specific PCR product. 
TaqMan is an oligonucleotide probe, which consistes of a fluorophore (reporter) 
at the 5ʹ-end and a quencher at the 3ʹ-end (Fig. 8). As long as the quencher (Q) 
is close to the reporter (R), it prevents the emission of the fluorescence. When 
the DNA polymerase extends the primer, the activity of 5ʹ-3ʹ exonuclease of 
polymerase cleaves the probe inhibiting the activity of the quencher and 
releasing the fluorescence of the reporter (Fig. 9). 
 
Figure 8 Diagrammed structure of TaqMan showing oligonucleotide with reporter at 5ʹ-end and 
quencher at 3ʹ-end. 
The geometric increase of the fluorescence, which is related to the exponential 
increase of the product, is detected and measured in RT-PCR at each cycle 
allowing the determination of the threshold cycle (Ct). 
Threshold cycle is the cycle at which the instrument can distinguish the 
fluorescence emitted by amplification of the gene from the background noise, 
and it is very important to the accuracy of the resultes. 
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The efficiency of RT-PCR can be calculated using the slope of the  standard 
curve, which is automaticily made by LightCycler 480 software from readings of 
the amplification of the plasmid dilution series, according to this equation: 
E=10[-1/slope] 
Where: 
E: Real-Time PCR efficiency  
 
Figure 9 The principle of TaqMan probe work. At the first the reporter fluorescence is 
quenched, when an extension of the  primer by DNA polymerase takes place,  the probe is 
cleaved and a emission of the reporter is detected. 
To prepare a master mix for RT-PCR the components in tables (5, 6, 7, and 8) 
were pipetted. 
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  Table 5 The components and their amounts and final concentration applied for RT-PCR of Mx1   
gene. 
 
 
 
 
 
hu Mx1 gene 
Component Amount Final concentration 
H2O 3.6 µl - 
MgCl2 25 mM 4 µl 5 mM 
10 x Taq-buffer 2 µl 1x 
TE-SS 40 ng/µl 2 µl 2  ng/µl 
DMSO  1 µl 5 % 
Tween 20 10 % 1 µl 0.5 % 
BSA 20 ng/µl 1 µl 0.5  ng/µl 
d’NTPs 10 mM 0.5 µl 200 nmol 
Probe Nr°. 34 1 µM 0.4 µl 20 nmol 
Primer F  Nr°. 153 10 µM  0.4 µl 250 nmol 
Primer R Nr°. 154 10 µM 0.5 µl 250 nmol 
Taq 5 U/ µl 0.1 µl 0.5 U 
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Table 6 The components and their amounts and final concentration applied for RT-PCR of IRF7 
gene. 
hu IRF7 gene 
Component Amount Final concentration 
H2O 4.4 µl - 
MgCl2 25 mM 3.2 µl 4 mM 
10 x Taq-buffer 2 µl 1x 
TE-SS 40 ng/µl 1 µl 2 ng/µl 
DMSO  1 µl 5 % 
Tween 20 10 % 1 µl 0.5 % 
BSA 20 ng/µl 0.5 µl  0.5 ng/µl 
d’NTPs 10 mM 0.4 µl 200 nmol 
Probe Nr°. 31 1 µM 0.4 µl 20 nmol 
Primer F Nr°. 163 10 µM  0.5 µl 250 nmol 
Primer R Nr°. 164 10 µM 0.5 µl 250 nmol 
Taq 5 U/µl 0.1 µl 0.5 U 
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Table 7 The components and their amounts and final concentration applied for RT-PCR of 
GAPDH gene. 
hu GAPDH gene 
Component Amount Final concentration 
H2O 6 µl - 
MgCl2 25 mM 1.6 µl 2 mM 
10 x Taq-buffer 2 µl 1x 
TE-SS 40 ng/µl 1 µl 2 ng/µl 
DMSO  1 µl 5 % 
Tween 20 10 % 1 µl 0.5 % 
BSA 20 ng/µl 0.5 µl  0.5 ng/µl 
d’NTPs 10 mM 0.4 µl 200 nmol 
Probe Nr°. 25 1 µM 0.4 µl 20 nmol 
Primer F Nr°. 23 10 µM  0.5 µl 250 nmol 
Primer R Nr°. 24 10 µM 0.5 µl 250 nmol 
Taq 5 U/µl 0.1 µl 0.5 U 
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Table 8 The components and their amounts and final concentration applied for RT-PCR of 
CCL20 gene. 
hu CCL20 gene 
Component Amount Final concentration 
H2O 4.4 µl - 
MgCl2 25 mM 3.2 µl 4 mM 
10 x Taq-buffer 2 µl 1x 
TE-SS 40 ng/µl 1 µl 2 ng/µl 
DMSO  1 µl 5 % 
Tween 20 10 % 1 µl 0.5 % 
BSA 20 ng/µl 0.5 µl  0.5 ng/µl 
d’NTPs 10 mM 0.4 µl 200 nmol 
Probe Nr°. 39 1 µM 0.4 µl 20 nmol 
Primer F Nr°. 7 10 µM  0.5 µl 250 nmol 
Primer R Nr°. 53 10 µM 0.5 µl 250 nmol 
Taq 5 U/µl 0.1 µl 0.5 U 
 
Master mix  was distributed to 96 wells PCR plate as 15µl per well. Afterwards, 
5µl of the standard was added to the first row and 5µl of the diluted cDNA to the 
other rows of the plate, where the standard was diluted in TE-Salmon Sperm 5 
ng/µl. 
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Table 9 The studied genes and their corresponded standards. 
Studied gene  Standard 
 
hu Mx1 
 Plasmid P BSK I+ hu Mx1 
              4948 bp 
              4550bp 
 
hu IRF7 
Plasmid P GEX-5x-2-hu IRF7 
             6400 bq 
             26 ng/µl Nanodrop (miniprep) 
 
hu GAPDH 
Plasmid P CMV-SPORT 6-hu GAPDH 
             (4,35 µg/µl) 
 
 
hu CCL20 
Plasmid P DNR-LIB-hu Mip3a(CCL20) Nr. 365 
             5020 bp 
             2360ng/µl  
 
The PCR programm applied for LightCycler for Universal ProbeLibrary UPL 
probes was as following: 
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Table 10 PCR-program for LightCycler. 
Programm Function Temperature Time Cycles 
 Pre-incubation Activation 95 ºC 10 min 1 cycle 
 
Touchdown 
Denaturation 95 ºC 5 sec  
10 cycles Annealing 65 ºC 5 sec 
Annealing 62 ºC 10 sec 
 
Amplification 
Denaturation 95 ºC 15 sec  
45 cycles Annealing 55 ºC 30 sec 
Amplification 62 ºC 30 sec 
 
At the end, the RT-PCR product can be quantified depending on the known 
threshold cycle (Ct) and the known standard curve. 
 
 
 
 
 
 
 
 
 
38 
 
7. Results 
In this study we examined the possible response of HPV-transformed (non-
malignant as well as malignant cells) and normal human keratinocytes to the 
cytokines TNFα and IFNβ. 
Major interest was to explore differences in expression of the transcription factor 
IRF7. Eight cell lines including HPV-negative primary keratinocytes, in vitro 
transformed HPV-positive keratinocytes and HPV-positive cervical carcinoma 
cells were stimulated with TNFα, IFNβ or in combination for 16 hours. RNA was 
isolated, cDNA was synthesized and quantitative RT-PCR was done to 
investigate the expression of four genes comprising IRF7, Mx1 as a further IFNβ-
responsive gene, CCL20 as a further TNFα-responsive gene and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as a house keeping gene. Gene 
expression of IRF7, Mx1 and CCL20 was normalized to GAPDH. Expression of 
IRF7, Mx1 and CCL20 in relation to GAPDH of non-stimulated cells was set at 1. 
7.1 Evaluation of IRF7 expression in primary human keratinocytes 
EXLN and NFK were treated with 1×103 U/ml TNFα and/or 1×102 U/ml IFNβ for 
16 hours. mRNA expression of IRF7 was quantified by quantitative RT-PCR. 
Stimulation with TNFα only slightly induced IRF7 in both cell types. IFNβ 
increased IRF7 expression 5-fold in EXLN cells and significantly 8-fold in NFK13 
cells (***p ≤ 0.001) compared to non-stimulated cells. The co-stimulation with 
TNFα and IFNβ led to the strongest induction of IRF7 in both cell types reaching 
significantly about 8-folds in EXLN cells and more than 15-fold in NFK13 (***p ≤ 
0.001) (Fig. 10). 
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Figure 10 IRF7 expression in HPV-negative primary keratinocytes after stimulation with 
TNFα, IFNβ or co-stimulation. 1×10
6
 EXLN (A) or NFK (B) cells were stimulated with medium, 
TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus IFNβ. After 16 hours mRNA was isolated 
from the cells and quantified by real-time PCR for IRF7 in relation to GAPDH. Shown are the 
mean values from three independent experiments performed in duplicates ± SD. Asterisks 
represent statistical significance (*p ≤ 0.05, ***p ≤ 0.001). n.s. not significant. 
7.2 Evaluation of IRF7 expression in in-vitro transformed HPV16 or 18 
keratinocytes 
HPK1A cell line (HPV16-positive) stimulated with TNFα showed very slight 
induction of IRF7 expression. Up to 14-fold significant increase was observed 
when cells were treated with IFNβ and 16-fold in response to both stimuli (***p ≤ 
0.001) (Fig. 11A). 
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K51 (HPV18-positive) stimulated with TNFα expressed significantly IRF7 more 
than 2-fold. IRF7 expression increased significantly to about 10-fold in response 
to IFNβ and almost 14-fold in response to TNFα and IFNβ together (***p ≤ 0.001) 
(Fig. 11B).  
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Figure 11 IRF7 expression in in vitro immortalized human keratinocytes after stimulation 
with TNFα, IFNβ or co-stimulation. 1×10
6
 HPK1A (A) or K51 (B) cells were stimulated with 
medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus IFNβ. After 16 hours mRNA was 
isolated from the cells and quantified by real-time PCR for IRF7 in relation to GAPDH. Shown are 
the mean values from three independent experiments performed in duplicates ± SD. Asterisks 
represent statistical significance (***p ≤ 0.001). 
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7.3 Evaluation of IRF7 expression in HPV16-or 18-positive cervical cancer 
cell lines  
Different HPV16- and HPV18-positive cervical cancer cell lines were stimulated 
with TNFα, IFNβ or in combination and IRF7 expression was analyzed. 
Treatment of HPV16-positive human cervical carcinoma cells CaSki with TNFα 
did not trigger a notable induction of IRF7 expression. This expression increased 
significantly 11-fold after stimulation with IFNβ alone and approximately 14 folds 
after co-stimulation with TNFα and IFNβ (***p ≤ 0.001) (Fig. 12A). The similar 
pattern was observed for SW756 cell lines (Fig. 12C). IRF7 expression in 
HPV18-positive human cervical carcinoma cells C4-I showed significantly an 
induction up to 4-fold in response to TNFα, 2-fold in response to IFNβ and 5 folds 
after co-stimulation with both cytokines (***p ≤ 0.001) (Fig. 12B). Furthermore, 
IRF7 expression was also elucidated in human adenocarcinoma HeLa. TNFα 
only slightly induced IRF7 expression. This induction reached significantly 8-fold 
after stimulation with IFNβ (***p ≤ 0.001). When the cells were treated with both 
stimuli, IRF7 expression raised insignificantly up to 4-fold (Fig. 12D). 
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Figure 12 IRF7 expression in HPV16-or 18-positive cervical cancer cell lines after 
stimulation with TNFα, IFNβ or co-stimulation. 1×10
6
 CaSki (A), C4-I (B), SW756 (C) or HeLa 
cells (D) were stimulated with medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus 
IFNβ. After 16 hours mRNA was isolated from the cells and quantified by real-time PCR for IRF7 
in relation to GAPDH. Shown are the mean values from three independent experiments 
performed in duplicates ± SD. Asterisks represent statistical significance (*p ≤ 0.05; ***p ≤ 0.001). 
n.s. not significant. 
In summary, the IRF7 response in HPV-positive cells was compared to that 
obtained in NFK (Fig. 13). 
In all TNFα-treated cells, IRF7 induction was at the similar level as for NFK, 
except C4-I and SW756 cell lines. In C4-I the IRF7 expression was significantly 
higher, while in SW756 significantly lower. 
The similar pattern was observed for TNFα/IFNβ synergism, which was 
significantly less effective only for C4-I cells, compare to NFK. 
IFNβ-mediated increase in IRF7 expression was significantly higher only in 
HPK1A cells, while in C4-I strongly reduced. For other HPV-positive cell lines, 
the IFNβ-mediated response was at least at the same level as for NFK.  
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Figure 13 TNFα and IFNβ-mediated IRF7 induction in mucosal human keratinocytes. 
Asterisks represent statistical significance (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). n.s. not significant. 
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7.4 Evaluation of Mx1 expression in primary human keratinocytes 
EXLN and NFK were treated with 1×103 U/ml TNFα and/or 1×102 U/ml IFNβ for 
16 hours. mRNA expression of Mx1 was quantified by quantitative RT-PCR. No 
notable induction of Mx1 expression was observed after stimulation with TNFα. 
When the cells were stimulated with IFNβ, Mx1 expression increased up to 3-fold 
in EXLN and more than 20-fold in NFK. Stimulation with both stimuli increased 
Mx1 expression 4-fold in EXLN and significantly 20-fold in NFK (Fig. 14).    
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Figure 14 Mx1 expression in HPV-negative primary keratinocytes after stimulation with 
TNFα, IFNβ or co-stimulation. 1×10
6
 EXLN (A) or NFK (B) cells were stimulated with medium, 
TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus IFNβ. After 16 hours mRNA was isolated 
from the cells and quantified by real-time PCR for Mx1 in relation to GAPDH. Shown are the 
mean values from three independent experiments performed in duplicates ± SD. Asterisks 
represent statistical significance (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). n.s. not significant. 
7.5 Evaluation of Mx1 expression in in-vitro transformed HPV16 or 18 
keratinocytes 
HPK1A (HPV16-positive) showed no induction of Mx1 expression upon 
stimulation with TNFα. Mx1 expression increased significantly 60-fold in 
response to treatment with IFNβ only or plus TNFα (***p ≤ 0.001) (Fig. 15A). 
K51 (HPV18-positive) keratinocytes treated with TNFα expressed Mx1 3-fold. 
When the cells were stimulated with IFNβ only or plus TNFα, Mx1 expression 
increased significantly up to 14-fold (***p ≤ 0.001) (Fig. 15B). 
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Figure 15 Mx1 expression in in vitro immortalized human keratinocytes after stimulation 
with TNFα, IFNβ or co-stimulation. 1×10
6
 HPK1A (A) or K51 (B) cells were stimulated with 
medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus IFNβ. After 16 hours mRNA was 
isolated from the cells and quantified by real-time PCR for Mx1 in relation to GAPDH. Shown are 
the mean values from three independent experiments performed in duplicates ± SD. Asterisks 
represent statistical significance (***p ≤ 0.001). n.s. not significant. 
7.6 Evaluation of Mx1 expression in HPV16-or 18-positive cervical cancer 
cell lines  
CaSki (HPV16-positive) showed no induction of Mx1 after treatment with TNFα. 
The cells expressed Mx1 significantly 19-fold in response to IFNβ and 20-fold in 
response to both stimuli (***p ≤ 0.001) (Fig. 16A). 
C4-I (HPV18-positive) did not express an induction of Mx1 after stimulation with 
TNFα, IFNβ or in combination (Fig. 16B).  
No induction of Mx1 expression was observed in SW756 (HPV18-positive) 
treated with TNFα. Stimulation with IFNβ only or plus TNFα induced significantly 
Mx1 expression 70-fold (***p ≤ 0.001) (Fig. 16C). 
HeLa (HPV18-positive) stimulated with TNFα expressed Mx1 2-fold. After 
treatment with IFNβ, Mx1 expression increased 6-fold. A significant induction of 
Mx1 expression was observed in HeLa cells treated with TNFα and IFNβ (***p ≤ 
0.001) (Fig. 16D). 
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Figure 16 Mx1 expression in HPV16-or 18-positive cervical cancer cell lines after 
stimulation with TNFα, IFNβ or co-stimulation. 1×10
6
 CaSki (A), C4-I (B), SW756 (C) or HeLa 
(D) cells were stimulated with medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus 
IFNβ. After 16 hours mRNA was isolated from the cells and quantified by real-time PCR for Mx1 
in relation to GAPDH. Shown are the mean values from three independent experiments 
performed in duplicates ± SD. Asterisks represent statistical significance (*p ≤ 0.05; ***p ≤ 0.001). 
n.s. not significant. 
In summary, the Mx1 response in HPV-positive cells was compared to that 
obtained in NFK (Fig. 17). 
No notable induction of Mx1 expression was observed in all TNFα-treated cells 
as for NFK.  
Except K51 and HeLa cells, the cells expressed IFNβ-mediated Mx1 at least at 
the same level as for NFK. IFNβ-mediated increase in Mx1 expression was 
significantly higher only in SW756 cells. 
The similar pattern was observed for TNFα/IFNβ synergism, which was 
significantly more effective for HPK1A and SW756 cells, compare to NFK. 
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Figure 17 TNFα and IFNβ-mediated Mx1 induction in mucosal human keratinocytes. 
Asterisks represent statistical significance (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). n.s. not significant. 
7.7 Evaluation of CCL20 expression in primary human keratinocytes 
An induction 6-fold of CCL20 expression in EXLN keratinocytes was observed in 
response to TNFα. The induction increased significantly 8-fold in cells treated 
with TNFα and IFNβ (***p ≤ 0.001). No response was seen upon stimulation with 
IFNβ (Fig. 18A). 
Stimulation of NFK keratinocytes with TNFα only or plus IFNβ caused 
significantly an induction of CCL20 expression about 5 folds (***p ≤ 0.001). A 
suppression of CCL20 expression occurred when the cells were treated with 
IFNβ only (Fig.18B). 
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Figure 18 CCL20 expression in HPV-negative primary keratinocytes after stimulation 
with TNFα, IFNβ or co-stimulation. 1×10
6
 EXLN (A) or NFK (B) cells were stimulated with 
medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus IFNβ. After 16 hours mRNA was 
isolated from the cells and quantified by real-time PCR for CCL20 in relation to GAPDH. Shown 
are the mean values from three independent experiments performed in duplicates ± SD. Asterisks 
represent statistical significance (**p ≤ 0.01; ***p ≤ 0.001). n.s. not significant. 
7.8 Evaluation of CCL20 expression in in-vitro transformed HPV16 or 18 
keratinocytes 
HPK1A keratinocytes expressed CCL20 significantly 110-fold in response to 
TNFα, 820-fold in response to TNFα accompanied with IFNβ and up to 10-fold 
after treatment with IFNβ only (***p ≤ 0.001) (Fig. 19A). 
K51 keratinocytes showed an induction of CCL20 expression 10-fold after 
stimulation with TNFα and 8-fold upon stimulation with TNFα plus IFNβ. The cells 
treated with IFNβ showed no induction of CCL20 expression (Fig.19B). 
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Figure 19 CCL20 expression in in vitro immortalized human keratinocytes after 
stimulation with TNFα, IFNβ or co-stimulation. 1×10
6
 HPK1A (A) or K51 (B) cells were 
stimulated with medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus IFNβ. After 16 
hours mRNA was isolated from the cells and quantified by real-time PCR for CCL20 in relation to 
GAPDH. Shown are the mean values from two independent experiments performed in duplicates 
± SD. Asterisks represent statistical significance (*p ≤ 0.05; ***p ≤ 0.001). 
7.9 Evaluation of CCL20 expression in HPV16-or 18-positive cervical cancer 
cell lines  
CaSki keratinocytes stimulated with TNFα expressed CCL20 110-fold. An 
induction of CCL20 expression up to 155-fold was observed after co-stimulation 
with TNFα and IFNβ. Treatment with IFNβ only caused no induction of CCL20 
expression (Fig. 20A). 
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In response to TNFα, CCL20 expression increased 20-fold in C4-I cells. CCL20 
expression raised 30-fold, when the cells were treated with TNFα and IFNβ. After 
stimulation with IFNβ, CCL20 expression was induced 6-fold (Fig. 20B). 
SW756 keratinocytes showed an induction of CCL20 expression 39-fold in 
response to TNFα. Co-stimulation with TNFα and IFNβ increased CCL20 125-
fold. CCL20 expression raised 2-fold in cells treated with IFNβ (Fig. 20C). 
HeLa keratinocytes expressed CCL20 37-fold in response to TNFα and 
significantly up to 40-fold after treatment with TNFα and IFNβ.  No induction was 
observed in HeLa cells stimulated with IFNβ (Fig. 20D). 
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Figure 20 CCL20 expression in HPV16-or 18-positive cervical cancer cell lines after 
stimulation with TNFα, IFNβ or co-stimulation. 1×10
6
 CaSki (A), C4-I (B), SW756 (C) or HeLa 
(D) cells were stimulated with medium, TNFα (1×10
3
 U/ml), IFNβ (1×10
2
 U/ml) and TNFα plus 
IFNβ. After 16 hours mRNA was isolated from the cells and quantified by real-time PCR for 
CCL20 in relation to GAPDH. Shown are the mean values from two independent experiments 
performed in duplicates ± SD. Asterisks represent statistical significance (*p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001). n.s.not significant. 
In summary, the CCL20 response in HPV-positive cells was compared to that 
obtained in NFK (Fig. 21). 
All cells treated with TNFα expressed CCL20, significantly only in HPK1A and 
HeLa cells, more than NFK. 
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Except K51, the similar pattern was observed for TNFα/IFNβ synergism, which 
was significantly more effective for HPK1A, compare to NFK. 
HPK1A cells treated with IFNβ expressed significantly CCL20 more than NFK, 
while other cells did not respond to the treatment with IFNβ. 
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Figure 21 TNFα and IFNβ-mediated CCL20 induction in mucosal human keratinocytes. 
Asterisks represent statistical significance (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). n.s. not significant. 
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7.10 Comparison between IRF7 expression and Mx1 expression in HPV 
negative and HPV-positive keratinocytes 
Our results corresponded to the previous observations which referred firstly to 
the ability of interferon beta to induce Mx1 expression and secondly to the 
inability of TNFα to do that (Holzinger et al, 2007; Aebi et al, 1989; Horisberger, 
1992; Simon et al, 1991). Compared to Mx1 expression, it could be noticed that 
the IRF7 expression was slightly induced after stimulation with TNFα and the 
highest induction was reported in C4-I cells. In the context of investigating of the 
effects of interferon beta on the IRF7 expression in comparison with an IFN-
inducible gene (Mx1), our findings referred to an induction of IRF7 expression 
less than Mx1 expression except in three cell lines (EXLN, C4-I, and HeLa). The 
similar pattern was observed after co-stimulation with TNFα and IFNβ (Fig. 22). 
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Figure 22 TNFα and IFNβ-mediated IRF7 induction compared to TNFα and IFNβ-mediated 
Mx1 in mucosal human keratinocytes. Asterisks represent statistical significance (***p ≤ 
0.001). 
7.11 Comparison between IRF7 expression and CCL20 expression in 
HPV-negative and HPV-positive keratinocytes 
According to the comparison between IRF7 expression and CCL20 expression in 
all studied cell lines, we could report that the stimulation with TNFα caused an 
increasing in IRF7 expression less than CCL20 expression in all cells. In 
contrast, IFNβ-mediated IRF7 expression was greater than IFNβ-mediated 
CCL20 expression in all cell lines. Moreover, the treatment with both stimuli 
TNFα and IFNβ increased IRF7 expression more than CCL20 expression in all 
cell lines except in EXLN, NFK and K51 cells (Fig. 23).   
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Figure 23 TNFα and IFNβ-mediated IRF7 induction compared to TNFα and IFNβ-mediated 
CCL20 in mucosal human keratinocytes. Asterisks represent statistical significance (***p ≤ 
0.001). 
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8. Discussion 
More than 99% of cervical carcinomas harbour HPV, especially HPV16 and 
HPV18 and these both genotypes are together responsible for 70% of cervical 
carcinomas (Bosch et al, 2008; Zur Hausen, 1990). Accordingly, extensive 
studies have been carried out to investigate how this virus can escape the 
immune system and persist in the cervical epithelium eventually leading to 
cancer. Cytokines, particularly IFNs, are an important part of the host defense 
against viral infection. It has been proposed that oncoproteins of high-risk HPV 
can suppress type I IFN signaling.  
Extensive attempts have been undertaken to study the impact of treatment of 
HPV-induced lesions with exogenous IFNs. Different observations were made. 
Lesions comprising episomal DNA have been completely removed, while lesions 
with integrated copies of viral DNA have been resistant (Beglin et al, 2009; 
Koromilas et al, 2001).   
HPV is double-stranded DNA virus. It has been speculated that its genome can 
be recognized by TLR9 leading to activate the MyD88-dependent pathway. 
In vitro, there are indications that HPV-induced triggering of TLR9 responses 
occurs (Hasan et al, 2007). TLRs activation, in turn, has been shown to induce 
IRF7 (Fig. 5) (Kawai & Akira, 2010). Upon viral infection IRF3 may be 
phosphorylated as well translocated resulting in production of IFNα and IFNβ 
which induce the IRF7 expression (Yoniyama et al, 1998; Juang et al, 1998; Sato 
et al, 2000; Lin et al; 1998; Sato et al, 1998). 
Numerous previous studies have reported that IFNβ can induce the IRF7 
expression through the JAK-STAT signaling pathway by forming ISGF3 complex 
(STAT1, STAT2, and IRF9) on ISRE (Fig. 3) (Silvennoinen et al, 1993; Katze et 
al; 2002; Velazquez et al, 1992; Darnell et al, 1994; Koromilas et al, 2001). 
Research has extensively concentrated on the mechanisms by which HPV can 
modify the cellular response to the treatment with cytokines such as TNFα and 
IFNβ. Of note, our group has recently shown that IRF7 binds to the HPV DNA 
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non-coding region thereby inducing HPV8 late promoter (Oldak et al, 2011). 
Thus, IRF7 is not only part of an antiviral response but may also have positive 
effects on HPV gene expression.   
Lu and others (2002) have reported previously that TNFα can induce IRF7 
expression in human peripheral blood monocytes through NF-κB signaling 
pathway. 
This study showed that TNFα has only limited ability to induce IRF7 expression in 
normal primary keratinocytes, in vitro HPV16- or HPV18-immortalized 
keratinocytes, HPV18-positive human adenocarcinoma HeLa and in HPV18-
positive human cervical carcinoma C4-I cells. No induction was found in HPV18-
positive cells of a differentiated cervical squamous cell carcinoma (SW756) and 
HPV16-positive human cervical carcinoma cells (CaSki). This may indicate that 
HPV16 has the ability to disrupt the TNFα signaling pathway. In productively 
infected epithelium HPV DNA exists as episomal genome. Here, the function of 
the E2 protein is retained repressing both oncoproteins E6 and E7. In contrast, in 
malignant cells, most often integration of viral DNA into host genome takes place 
in the region of the E2 gene resulting in disruption of its function. This leads to 
the upregulation of E6 and E7 oncoproteins which promote malignant 
transformation (Tonon et al, 2001; Dowhanick et al, 1995). Moreover, it has been 
observed that the HPV16 E6 and E7 reduce the activity of NF-κB in HPV16-
positive human cervical carcinoma cells (CaSki) (Havard et al, 2002). In 
agreement with the past findings, our data showed suppression of the IRF7 
expression in HPV16-positive human cervical carcinoma cells (CaSki). On the 
other hand, we observed suppression of IRF7 expression in HPV18-positive 
human adenocarcinoma HeLa in comparison with the HPV-negative 
keratinocytes and HPV18-positive keratinocytes. Also, we observed an 
abrogation of the IRF7 expression in HPV18-positive cells of differentiated 
cervical squamous cell carcinoma (SW756). One can assume that the high levels 
of HPV18 or 16 E6 and E7 in the cervical cancer cells interfere with the TNFα 
signaling pathway. Only in C4-I cervical cancer cells and HPV-18 transformed 
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K51 cells, IRF7 expression was significantly stronger than in HPV-negative 
keratinocytes and HPV18-positive keratinocytes.   
Similarly, the effect of IFNβ on the IRF7 expression in the presence or absence 
of HPV was tested. Our data showed that the IFNβ had the capability to activate 
the IRF7 expression in HPV-negative primary keratinocytes, in vitro HPV16- or 
HPV18-immortalized keratinocytes and in HPV16- or HPV18-positive cancerous 
keratinocytes. However, the levels of the induction were different. In all tested 
HPV-positive carcinoma cell lines, IFNβ-mediated IRF7 induction was at least as 
good as in NFK. Exceptions were C4-I cells. In HeLa cells and C4-1 cells the 
TNFα/IFNβ synergism was also less effective. We demonstrated that in HPV16- 
or HPV18-positive cells the IFNβ-mediated induction of IRF7 expression was in 
some cases even higher than in the HPV-negative cells. This was obviously not 
due to episomal HPV genomes, since both in in vitro transformed as well as 
HPV-positive cancerous keratinocytes the viral DNA is integrated into the host 
genome. In most cases this integration is associated with deletion of regions 
including the E1, E2, E4, and E5 open reading frames (ORFs) and retention of 
E6 and E7 genes (Shirasawa et al, 1987). In this context, an interest study has 
shed light on the role of HPV16 E5 in IFNβ signaling pathway and it has reported 
that HPV16 E5 induces IFNβ expression through stimulation of IRF1 (Muto et al, 
2011). Consistent with the mentioned study, our data showed high expression of 
IRF7 in HPV16 positive keratinocytes HPK1A. This may be because of the 
expression of E5 which has been recently identified as a positive regulator of the 
IFNβ expression via induction of IRF1. This hypothesis should, however, be 
tested. Moreover, it can be assumed that this did not account for the slightly 
stronger inducibility in the cancer cell lines CaSki and SW756. 
Barnard and McMillan (1999) have demonstrated the suppression of IFNα-
inducible gene expression by HPV16 E7 through the interaction between E7 and 
IRF9 (p48) which is an important part of the ISGF3, so that this interaction 
inactivates the ISGR3 complex formation resulting in the hindering of the IFNα 
signaling pathway. Furthermore, it has been reported that the HPV16 E7 has the 
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opportunity to bind to IRF1, which is a transcription factor mediates the IFN 
signaling induced by viral infection or IFN treatment by binding to ISRE in the 
promoter of IFN-inducible genes causing transcriptional activation. So that, the 
interference of HPV16 E7 with IRF1 creates repression of the transactivation 
activity of IRF1 leading to suppression of the response to IFN-treatment (Park et 
al, 2000; Taniguchi et al, 1998). Moreover, it has been observed that HPV18 E6 
binds to Tyk2 blocking the activation of the Jak-Stat pathway by IFNα (Li et al, 
1999). In contrast to this, our data demonstrated that in most HPV-positive 
keratinocytes and cancer cells, IFNβ signaling leading to IRF7 induction is not 
disturbed.  
In addition, we quantified the IRF7 expression by RT-PCR after co-stimulation 
with TNFα and IFNβ in HPV-negative normal keratinocytes, in vitro HPV16- or 
HPV18-immortalized keratinocytes and in HPV16- or HPV18-positive cancerous 
keratinocytes. And as a result, we documented that all studied cell lines, except 
HeLa, presented an IRF7 expression in response to the stimulation with both 
cytokines TNFα and IFNβ greater than in response to each cytokine separately. 
Mx1 is an interferon-stimulated gene which can be induced in response to type I 
IFN and slightly in response to IFNγ and type III IFN (Holzinger et al, 2007; Aebi 
et al, 1989; Horisberger, 1992). Contrarily, it has been demonstrated that Mx1 
gene dose not respond to the stimulation with TNFα (Simon et al, 1991). In our 
experiments, we used Mx1 as a positive control to the activity of IFNβ, and we 
found an induction of this gene expression after treatment with IFNβ alone or in 
addition to TNFα in all studies cell lines except C4-I cells which did not show any 
response. This indicated that the response to exogenous IFNβ  was retained in 
most HPV-positive cells not only with respect to IRF7 but also the classical IFN-
inducible gene Mx1. Additionally, there was remarkable the big difference in Mx1 
expression between the exocervical keratinocytes and foreskin keratinocytes, 
and this difference may be dependent on the cell phenotype. Our experiments 
showing Mx1 expression after stimulation with IFNβ alone or combined to TNFα 
indicated that TNFα has not the ability to reinforce the effect of IFNβ. 
66 
 
In the same way, the expression of CCL20 was investigated in this study as a 
control of the TNFα bioactivities. It has been previously reported that the 
expression of CCL20 can be potently induced upon treatment with TNFα through 
the NF-kB signaling pathway (Reibman et al, 2002; Nakayama et al, 2001; Fujiie 
et al, 2001; Hosokawa et al, 2005; Tohyama et al, 2001). Consistent with the 
past findings, our result documented an induction of the CCL20 expression in 
response to TNFα in all cell lines, however, again with strong differences level of 
induction particularly was observed in in vitro HPV16-immortalized foreskin 
keratinocytes and also in HPV18-positive cancerous cells C4-I. 
In summary, this study suggests that TNFα has limited ability to induce IRF7 
expression in HPV-transformed and normal human keratinocytes. This induction 
is in some cases of HPV18-transformed keratinocytes stronger than in HPV-
negative keratinocytes. In addition, our data show that IRF7 expression induced 
by exogenous IFNβ is retained in most HPV-positive malignant and non-
malignant keratinocytes. Except HeLa cells, TNFα and IFNβ induce 
synergistically IRF7 expression in HPV-negative and HPV-transformed 
keratinocytes. 
The present work demonstrates that the exogenous IFNβ signaling leading to 
induction of Mx1 expression and TNFα signaling leading to induction of CCL20 
are not disturbed in HPV-transformed and normal human keratinocytes. 
Thus, HPV16 and HPV18 may have no negative effects on the response of 
mucosal human keratinocytes to the treatment with TNFα and/or IFNβ. 
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